By controlling the expressions of genes involved in lipid metabolism and inflammation, the MEG3/EZH2/SIRT6 axis significantly suppressed lipid accumulation and inflammation in vitro, and NAFLD development in vivo. This evidence concerns the gene EZH2 and metabolic dysfunction-associated steatotic liver disease.